| abstract |
The present invention aims to provide antibodies or functional fragments thereof that bind to the human PGE 2 receptor subtype EP4 and inhibit the function of EP4. It is also intended to provide a medicament containing the antibody or a functional fragment thereof. Immune human PGE 2 receptor subtype EP4 in mouse, which was screened for the monoclonal antibody to inhibit intracellular cAMP increase due to EP4. In addition, the CDRs of the obtained monoclonal antibodies were sequenced. |